Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08049820 MR1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 short Modified release (MR) release rate (MR1) tablets under fasted conditions. |
| Treatment B | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 long MR release rate (MR2) tablets under fasted conditions. |
| Treatment C | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 Immediate Release (IR) tablets under fasted conditions. |
| Treatment D | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 MR2 tablets under fed conditions. |
| Treatment E | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 IR tablets under fed conditions. |
| Name | Type | Description |
|---|---|---|
| PF-08049820 MR1 | DRUG | Administered orally |
| PF-08049820 MR2 | DRUG | Administered orally |
| PF-08049820 IR | DRUG | Administered orally |
Inclusion Criteria: * Male and female participants of non-childbearing potential ≥18 years of age * BMI of 16-32 kg/m2; and a total body weight \>45 kg (99 lbs) * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures....
Top 20 of 26 competitors
PF-08049820 MR1 is an investigational small molecule being studied for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
PF-08049820 MR1 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in early-stage clinical development for atopic dermatitis.
PF-08049820 MR1 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 study has been completed, and the drug remains under evaluation for atopic dermatitis.
PF-08049820 MR1 has one completed Phase 1 trial, NCT07172321, which studied how different forms of the drug are absorbed into the bloodstream in healthy adults. The trial enrolled 12 participants in the United States and was a controlled, randomized study.
PF-08049820 MR1 is not FDA approved. It is an investigational drug in Phase 1 clinical development for atopic dermatitis. The completed trial, NCT07172321, was a pharmacokinetic study in healthy volunteers, and the drug has not yet progressed to later-stage trials.